Nintedanib in progressive fibrosing interstitial lung diseases

New England Journal of Medicine

Volumn 381, Issue 18, 2019, Pages 1718-1727

  Flaherty, Kevin R ^a   Wells, Athol U ^a,b,c   Cottin, Vincent ^d   Devaraj, Anand ^b,c   Walsh, Simon L F ^c   Inoue, Yoshikazu ^e   Richeldi, Luca ^f   Kolb, Martin ^g   Tetzlaff, Kay ^h,i   Stowasser, Susanne ^h   Coeck, Carl ^j   Clerisme Beaty, Emmanuelle ^h   Rosenstock, Bernd ^h   Quaresma, Manuel ^h   Haeufel, Thomas ^h   Goeldner, Rainer Georg ^h   Schlenker Herceg, Rozsa ^k   Brown, Kevin K ^l  

^a UNIVERSITY OF MICHIGAN   (United States)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d UNIVERSITÉ LYON 1   (France)

^e NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^g MCMASTER UNIVERSITY   (Canada)

^h BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j Boehringer Ingelheim   (Belgium)

^k BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^l DEPARTMENT OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; NINTEDANIB; PLACEBO; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; AGED; ARTICLE; BODY WEIGHT LOSS; BRONCHITIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; INTERSTITIAL PNEUMONIA; LIVER DYSFUNCTION; LUNG DIFFUSION CAPACITY; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; VOMITING; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFECT; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; VITAL CAPACITY;

AGED; DIARRHEA; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; VITAL CAPACITY;

EID: 85074307295     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1908681     Document Type: Article

References (27)

1. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018;198(5):e44-e68.
2. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med 2018; 378:1811-23.
3. Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res 2017; 4(1):e000212.
4. Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018; 51(5):1800692.
5. Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev 2019;28(151): 180100.
6. Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res 2019;20:57.
7. Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1434-45.
8. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014;349:209-20.
9. Redente EF, Aguilar MA, Black BP, et al. Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease. Am J Physiol Lung Cell Mol Physiol 2018;314:L998-L1009.
10. Huang J, Maier C, Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis 2017;76:1941-8.
11. Wollin L, Distler JHW, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J 2019;54(3).
12. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-87.
13. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82.
14. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med 2019;380:2518-28.
15. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010;35:1322-8.
16. Walsh SLF, Sverzellati N, Devaraj A, Keir GJ, Wells AU, Hansell DM. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax 2014; 69:216-22.
17. Salisbury ML, Gu T, Murray S, et al. Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory. Chest 2019;155:699-711.
18. Adegunsoye A, Oldham JM, Bellam SK, et al. Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases. Ann Am Thorac Soc 2019;16:580-8.
19. Guidance for industry: adaptive design clinical trials for drugs and biologics (draft guidance). Silver Spring, MD: Food and Drug Administration, 2013.
20. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
21. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King’s Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 2012;67:804-10.
22. Patel AS, Siegert RJ, Keir GJ, et al. The minimal important difference of the King’s Brief Interstitial Lung Disease questionnaire (K-BILD) and forced vital capacity in interstitial lung disease. Respir Med 2013;107:1438-43.
23. Sinha A, Patel AS, Siegert RJ, et al. The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference. BMJ Open Respir Res 2019;6(1):e000363.
24. Nolan CM, Birring SS, Maddocks M, et al. Kings Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference. Eur Respir J 2019;54(3).
25. Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis: an international working group report. Am J Respir Crit Care Med 2016;194:265-75.
26. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
27. Lancaster L, Crestani B, Hernandez P, et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res 2019; 6(1):e000397.